A Study of Lanabecestat (LY3314814) in Healthy Participants

Inclusion Criteria: \- Male participants: Will be sterile (including vasectomy) or agree to use an effective method of birth control and will not donate sperm during the study and for 3 months following the last dose of the investigational product \- Female participants: Women not of childbearing potential due to surgical sterilization or confirmed by medical history or menopause \- Are able to eat a high-fat, high-calorie meal within the defined time limit and abide by the food restrictions throughout the study Exclusion Criteria: * Have a history of or current, significant ophthalmic disease, as determined by the investigator or ophthalmologist * Have vitiligo or any other clinically significant disorder of skin pigmentation as determined by the investigator or dermatologist * History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs * History of previous or ongoing psychiatric disease/condition * Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study, or have a history of significant dysrhythmias or atrioventricular (AV) block (including first degree AV block). Participants with history of persistent PR interval greater than (\>)200 milliseconds (msec) will be excluded * Have prolonged Fridericia-corrected QT interval (QTcF) of \>470 msec * Have a clinically significant abnormal blood pressure or heart rate (supine) as determined by the investigator * Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs * Are unwilling to comply with the dietary requirements/restrictions during the study * Evidence of active renal disease (e.g, diabetic renal disease, polycystic kidney disease) or calculated creatinine clearance \<50 milliliters per minute (mL/min)